Harvard Bioscience Inc. (HBIO)

[surf1944]

MARKETS | 12/12/2012 @ 4:57PM |291 views
Harvard Bioscience Announces Filing of IPO Registration Statement for Harvard Apparatus Regenerative Technology
Comment Now Follow Comments
Harvard Bioscience (HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine, announced that its wholly-owned subsidiary, Harvard Apparatus Regenerative Technology, Inc., filed a registration statement with the SEC for an initial public offering, or IPO, of Harvard Apparatus Regenerative Technology’s common stock. Following the IPO, Harvard Apparatus Regenerative Technology will own Harvard Bioscience’s regenerative medicine device business, which develops life-saving medical devices in the field of regenerative medicine, including devices to be used by physicians for growing organs outside the body for transplant.

Following the IPO, Harvard Bioscience will own at least 80% of Harvard Apparatus Regenerative Technology’s common stock.

Harvard Bioscience intends to distribute its remaining interest in Harvard Apparatus Regenerative Technology to Harvard Bioscience’s shareholders in a pro-rata, tax-free dividend approximately 120 days following the closing of the IPO.

Summer Street Research Partners will act as sole book-running manager for the offering.